Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

For now though, any threat from Merck's drug is speculative. Lead study author Douglas Johns of Merck Research Labs acknowledged at that AHA while the initial results are encouraging, "more ...

Pakistan Navy and Pakistan Maritime Security Agency have seized a large consignment of drugs at sea. According to ISPR, in a joint anti-narcotics operation, PMSS Zhob seized a large quantity of ...